BioNTech Results Presentation Deck

BNT111: Off-the Shelf Therapeutic Vaccine for Melanoma Potential to Improve Outcomes in Combination with Anti-PD1 by Rescuing from T Cell Exhaustion BNT111 encodes 4 tumor-associated antigens covering >90% of cutaneous melanoma patients 1 24 DOD NY-ESO-1 Tyrosinase MAGE-A3 TPTE H AAAA H AAAA H AAAA AAAA nature² An RNA vaccine drives immunity in checkpoint- inhibitor-treated melanoma Ugur Sahin, Petra Oehm, [...]Özlem Türeci Tolerable safety as monotherapy and in combination with anti-PD1 Durable objective responses in CPI-experienced patients with unresectable melanoma • ORR: BNT111 monotherapy: 3/25 PR; 8/25 SD • ORR: 35% in combination with anti-PD1: 6/17 PR; 2/17 SD Clinical responses accompanied by strong CD4+ and CD8+ T cell immunity NY-ESO-1, New York esophageal squamous cell carcinoma-1; MAGE-A3, melanoma-associated antigen 3; TPTE, transmembrane phosphatase with tensin homology; AAAA, Poly-A tail; PD1, Programmed cell death protein 1; CPI, check point inhibitor; R/R, refractory/resistant; PR, partial response; SD, stable disease; ORR, Overall Response Rate; CD, Cluster of Differentiation; ¹Data on file; 2Sahin U, et al. Nature 2020; 585:107-112 (https://www.nature.com/articles/s41586-020-2537-9) BIONTECH

View entire presentation